Michael Pritchett, DO
Pulmonary Disease · Pinehurst, NCNPI 1023055761
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.0%), education and consulting fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 78.5% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2022 at $340,372 and has fallen 67.1% since, to $111,967 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,677 payments — averaging $788.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1M
- AstraZeneca$48K
- Ambu A/s$42K
- Actelion Pharmaceuticals US, Inc.$32K
- Galvanize Therapeutics, Inc$30K
- Ethicon Endo-surgery Inc.$20K
- plus $112K from 54 others
Across 84 payments — averaging $10,185 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$283K
- Galvanize Therapeutics, Inc$256K
- Ethicon Endo-surgery Inc.$110K
- United Therapeutics Corporation$79K
- Actelion Pharmaceuticals, Ltd$67K
- Serpex Medical Inc$35K
- plus $25K from 4 others
What the payments were for
- Consulting fees$191,59214%
- Speaking & faculty fees$700,75553%
- Travel & lodging$111,5718%
- Food & beverage$43,7273%
- Education$274,00321%
- Gifts$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$903,016
- DA VINCI SP$116,500
- TAGRISSO$38,759
- ALIYA SYSTEM$29,619
- UPTRAVI$25,749
- OPSUMIT$22,719
- superDimension$17,721
- CERTUS 140 MICROWAVE ABLATION SYSTEM$11,158
- Monarch Platform$10,178
- ILLUMISITE$8,729
- ION$8,400
- ORENITRAM$5,714
- HealthMyne$5,509
- XALKORI$5,500
- REMODULIN$5,364
- TYVASO$5,364
- NONE$3,920
- IMFINZI$3,202
- ACQUIRE$3,200
- NEUWAVE Flex Microwave Ablation System$1,726
How this compares
$1,321,747 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 11 | $257,112 |
| Tyvaso DpiTreprostinil | 11 | $253,584 |
| OfevNintedanib Esylate | 11 | $147,605 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $116,553 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 130 | $99,297 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $14,410 |
| Spiriva RespimatTiotropium Bromide | 23 | $11,652 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,799 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $10,133 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,318 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,253 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $2,516 |
| Omeprazole | 38 | $320 |
| Prednisone | 49 | $295 |
| Methylprednisolone | 18 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi | $32,167 | $257,11211 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $380 | $169,39055 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $830 | $122,025178 claims |
| Grifols USA, LLCProlastin C | $517 | $116,55311 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $47,804 | $16,05235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Pinehurst
- Bradley IcardPinehurst$299K
- Scott SkiboPinehurst$229K
- Adam BelangerPinehurst$96K
- Scott JohnsonPinehurst$24K
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Jill OharWinston Salem$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.